Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France. 

In this video interview, Dr Testa explains the technology behind the XLIMUS^® drug-eluting stent (Cardionovum^®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.

Specifically, the 6 to 9 months follow-up results showed that the XLIMUS^® DES was comparable to the Synergy™ DES on both primary endpoints (in-stent neointimal percent volume obstruction and in-stent neointimal volume). No difference was also found with respect to the secondary OCT endpoints as well as for clinical endpoints.¹

The study results confirm that the biological interaction of the XLIMUS^® and Synergy™ DES with the coronary artery is comparable and that translates in very reassuring OCT parameters at follow-up: as such, the XLIMUS^® DES is non-inferior to the Synergy™ DES.¹

References:

1. Testa L, Squillace M, Ventrella N, et al. A randomized control trial to assess optical coherence tomography parameters of the Xlimus drug-eluting stent: the XLIMIT trial. Front Cardiovasc Med 2023;10:1199475.